Western Blot vs Modified Two-Tier Testing in Lyme Disease

The 2017 Proposal to Replace Western Blot Testing

Lyme disease testing continues to evolve, but important limitations remain. In 2017, researchers proposed replacing Western blot testing with newer methods designed to simplify and standardize diagnosis.

This raises an important question: are newer Lyme disease tests actually better, or simply different? Understanding the strengths and limitations of each approach is critical for clinical decision-making.

In 2017, researchers from Massachusetts General Hospital and Harvard Medical School proposed eliminating the Western blot from Lyme disease diagnosis. :contentReference[oaicite:0]{index=0}

Their argument was straightforward: replace the traditional two-tier testing algorithm (ELISA followed by Western blot) with a combination of enzyme immunoassays—specifically, a whole-cell sonicate (WCS) EIA, C6 EIA, and VlsE chemiluminescence immunoassay (CLIA).

This approach, called Modified Two-Tier Testing (MTTT), aimed to improve early detection while eliminating the variability of Western blot interpretation.

Western blot testing had known limitations, including subjective band interpretation and reduced sensitivity in early infection. However, eliminating it entirely raised concerns about whether the replacement offered meaningful improvement.

---

Why There Was Resistance to Replacing Western Blot

The Western blot-based two-tier test provided serologic confirmation for some patients, particularly when ELISA results were positive or equivocal. It had been the standard approach since 1994.

While opinions differed regarding its sensitivity, especially in chronic presentations, it remained a familiar and widely used diagnostic tool.

The concern was not whether Western blot was imperfect—it clearly was—but whether the proposed alternative had demonstrated superior clinical performance.

---

The Sensitivity Problem With Both Approaches

When evaluated, both testing strategies showed limitations:

Traditional two-tier testing demonstrated limited sensitivity in early Lyme disease, while Modified Two-Tier Testing showed modest improvements but was based on small sample sizes.

Neither approach reliably detected all cases, particularly in early infection or complex presentations.

Changing testing methodology may improve workflow, but it does not change the underlying biology of Borrelia infection or the timing of antibody production.

---

What Actually Happened: FDA Clearance and Clinical Adoption

Beginning in 2019, certain Modified Two-Tier Testing protocols received FDA clearance. These approaches use two enzyme immunoassays rather than ELISA followed by Western blot.

However, Western blot testing was not eliminated. Both methods remain available, allowing clinicians to choose based on context.

---

Current State: Two Options, Same Limitations

Today, clinicians may use either traditional two-tier testing or Modified Two-Tier Testing.

Western blot provides antigen-specific band information, while MTTT offers standardization and automation. However, both detect antibodies rather than active infection.

Neither approach addresses early seronegativity, immune variability, or persistent symptoms following treatment.

---

Why Clinical Judgment Still Matters

This case illustrates a broader principle in Lyme disease care: laboratory testing supports diagnosis but does not replace clinical judgment.

Serologic testing is most reliable weeks after infection begins, often after early treatment opportunities have passed. Many patients do not present with classic findings, and some remain seronegative despite active infection.

When symptoms and exposure history suggest Lyme disease, clinical evaluation remains essential, even when laboratory results are inconclusive.

Patients may benefit from review of Lyme disease symptoms, understanding test accuracy, and guidance on testing approaches beyond standard algorithms.

---

Frequently Asked Questions

Is Modified Two-Tier Testing better than Western blot?
MTTT offers standardization but does not fully address early detection limitations. Both methods have similar constraints.

Can I still get Western blot testing?
Yes. Western blot remains available and is still used in clinical practice.

Which testing method should I use?
This decision depends on clinical context, timing, and physician judgment.

Why doesn’t either test work well early?
Both rely on antibody detection, which takes time to develop.

What if my test is negative but I have symptoms?
Negative testing does not rule out Lyme disease, particularly in early infection.

---

Clinical Takeaway

The debate over Western blot versus Modified Two-Tier Testing highlights a key limitation in Lyme disease diagnostics. While testing methods continue to evolve, both approaches share fundamental constraints related to antibody detection. Clinical judgment based on symptoms and exposure history remains central to diagnosis and treatment decisions.

---

---

Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.

Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention